Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 3 2Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Screening 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 171Docetaxel 163Paclitaxel 160Trastuzumab 151Capecitabine 130Tamoxifen 119Letrozole 105Epirubicin 93Doxorubicin 83Anastrozole 83exemestane 77Fulvestrant 75Carboplatin 64Fluorouracil 63Radiotherapy 61pertuzumab 59Gemcitabine 55Vinorelbine 43Goserelin 39eribulin 36130-nm albumin-bound paclitaxel 36palbociclib 32Bevacizumab 32ribociclib 30Zoledronic Acid 29Lapatinib 29Methotrexate 28Drug Therapy 28Chemotherapy, Adjuvant 28Ado-Trastuzumab Emtansine 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Genetic Testing × Breast × Clear all
NCT06058377 2026-05-27

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT03233191 2026-05-05

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
108,508 enrolled
Breast

Breast Screening

Data powered by HemOnc (CC BY 4.0) Colophon âš¡